SUMMARY
Myocardial infarction (MI) remains a dreadful disease around the world, causing irreversible sequelae that shorten life expectancy and reduce quality of life despite current treatment. Here, the authors engineered a cell-enriched myocardial graft, composed of a decellularized myocardial matrix refilled with adipose tissuederived progenitor cells (EMG-ATDPC). Once applied over the infarcted area in the swine MI model, the EMG-ATDPC improved cardiac function, reduced infarct size, attenuated fibrosis progression, and promoted neovascularization of the ischemic myocardium. The beneficial effects exerted by the EMG-ATDPC and the absence of identified adverse side effects should facilitate its clinical translation as a novel MI therapy in humans. Cardiac tissue engineering uses natural or synthetic support platforms generating functional grafts that can be tightly implanted over injured myocardium (5, 6) . For optimal cell seeding, the supporting material or scaffold should provide a biomimetic niche resembling the physiological microenvironment, supplying the necessary cues to direct cell differentiation and proliferation, and favoring electromechanical coupling with host tissue (7, 8) . Decellularized myocardial extracellular matrix meets these requirements because it preserves the native myocardium ultrastructure, mechanical properties, and local matrix milieu (9) (10) (11) (12) . A recent study reports a refined protocol for obtaining an optimal myocardial scaffold for recellularization (9) . Despite the favorable qualities of decellularized myocardial scaffolds, few studies have investigated their use in pre-clinical MI animal models. To date, only 1 report describes administration of a decellularized myocardial scaffold in swine, and it was a cell-free scaffold (13) .
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Novel Cell-Enriched Engineered Myocardial Graft Baseline CMR data analysis showed no differences between the studied groups (Supplemental Table 1 ). Figures 3D and 3E) . Figure 1 . Figure 6E ).
DISCUSSION
The present study is the first, to our knowledge, to The pATDPC lineage chosen to repopulate the scaffold has previously exhibited cardiomyogenic Perea-Gil et al.
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